SCHEMBL1751975

SCHEMBL1751975

Cc1cc(Cl)c(OCCOc2ccc(C3=C(C(=O)O)CN(C(=O)OC(C)(C)C)CC3)cc2)c(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.42
ESR2 Q92731 1/20 0.41
REN P00797 5/20 0.40
NR1H2 P55055 1/20 0.39
PPARG P37231 1/20 0.38
PPARA Q07869 1/20 0.38
CHRM5 P08912 1/20 0.38
CHRM1 P11229 1/20 0.38
GPR119 Q8TDV5 4/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
KDM4E B2RXH2 2/20 0.36
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
USP2 O75604 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1751338 0.91 CYP3A4 (0.41) CYP3A4ESR2RENNR1H2CHRM5
SCHEMBL4685482 0.89 CYP3A4 (0.45) CYP3A4RENPPARGPPARACHRM5
SCHEMBL1751769 0.88 ESR2 (0.39) ESR2NR1H2GPR119MEN1KMT2A
SCHEMBL5941966 0.87 ESR2 (0.39) ESR2NR1H2PPARGPPARACHRM5
SCHEMBL7026727 0.81 PPARG (0.41) ESR2NR1H2PPARGPPARACHRM5
SCHEMBL1752582 0.80 ACACB (0.40) ESR2NR1H2CHRM5CHRM1GPR119
SCHEMBL5941947 0.78 CHRM5 (0.40) ESR2NR1H2CHRM5CHRM1GPR119
SCHEMBL1752181 0.78 REN (0.70) CYP3A4REN
SCHEMBL25262018 0.77 ESR2 (0.45) ESR2NR1H2CHRM5CHRM1GPR119
SCHEMBL5668307 0.77 REN (0.41) CYP3A4RENGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968720-B2 Secondary amines as renin inhibitors ACTELION PHARMACEUTICALS LTD. (CH) 2011-06-28 US disclosed
US-20090176823-A1 Secondary Amines as Renin Inhibitors ACTELION PHARMACEUTICALS LTD. (CH) 2009-07-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176823-A1 Secondary Amines as Renin Inhibitors REN, ACE, AGTR1 CYP3A4 441/4885ESR2 3079/4885REN 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.